Developments in targeted therapy of advanced gastrointestinal stromal tumors

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 2, 2008, Pages 88-99

  Rutkowski, Piotr ^a   Symonides, Małgorzata ^a   Zdzienicki, Marcin ^a   Siedlecki, Janusz A ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

FMS like tyrosine kinase 3; GIST; PDGFRA B; Platelet derived growth factor receptor ; Rearranged during transfection; VEGFRs

Indexed keywords

AB 1010; ANTINEOPLASTIC AGENT; AUY 922; CD135 ANTIGEN; CEDIRANIB; CNF 2024; COLONY STIMULATING FACTOR RECEPTOR; DASATINIB; EVEROLIMUS; FLAVOPIRIDOL; IMATINIB; KOS 1022; MASATINIB; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NILOTINIB; OBLIMERSEN; OSI 930; PERIFOSINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SNX 5422; SORAFENIB; STA 9090; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTHYROIDISM; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHARMACOGENETICS; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; THROMBOSIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 55649094626     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208784638749     Document Type: Review

References (160)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152(5): 1259-1269.
2. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17 (10): 280-286.
3. D'Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12: 44-56.
4. Miettinen M,Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438(1): 1-12.
5. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in pre-imatinib mesylate era. Cancer 2005; 103: 821-829.
6. Corless CL, Fletcher JA,Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22(18): 3813-3825.
7. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23(23): 5357-5364.
8. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299(5607): 708-710.
9. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125(3): 660-667.
10. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279(5350): 577-580.
11. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol2001; 193(4): 505-510.
12. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160(5): 1567-1572.
13. Tosoni A, Nicolardi L, Brandes AA. Current clinical management of gastrointestinal stromal tumors. Expert Rev Anticancer Ther2004; 4(4): 595-605.
14. Corless CL, McGreevey L, Town A, et al. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J Mol Diagn 2004; 6(4): 366-370.
15. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007; 17(1): 3-7.
16. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31: 113-120.
17. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31: 1037-1051.
18. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465.
19. Heinrich MC, Rubin BP, Langley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 486-495.
20. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Sem Diagn Pathol 2006; 23: 91-102.
21. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121.
22. West, R.B., Van de Rijn, M.: US20060040292 (2001).
23. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1): 51-58.
24. Dematteo RP, Heinrich MC, El-Rifai WM,Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33(5): 466-477.
25. Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14(1): 134-142.
26. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14(7): 2018-2027.
27. Demetri GD. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am 2002; 16(5): 1115-1124.
28. Buchdunger, E., Capdeville, R, Demetri, G.D., et al.: EP1332137 (2003).
29. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl 2: S1-29; quiz S30.
30. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treamaent of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8(10): 3034-3038.
31. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 2007; 18 (10): x20-x24.
32. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5): 561-566.
33. Buchdunger E, Zimmermann J, Mett H. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995; 92(7): 2558-2562.
34. Buchdunger E, Zimmermann J, Mett H. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative. Cancer Res 1996; 56: 100-104.
35. Heinrich MC, Griffith DJ, Druker BJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96(3): 925-932.
36. Okuda K, Weisberg E, Gilliland D, Griffin J. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97(8): 2440-2448.
37. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20(36): 5054-5058.
38. Buchdunger E, Ciotfi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295(1): 13945.
39. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279(30): 31655-31663.
40. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358(9291): 1421-1423.
41. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002; 38 (5): S83-87.
42. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472-480.
43. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620-625.
44. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39(14): 2006-2011.
45. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26(4): 626-632.
46. Verweij J, Casail PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): 1127-1134.
47. Rutkowski P, Nowecki ZI, Debiec-Rychter M, et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol 2007; 133(9): 589-597.
48. Van Glabbeke M, M, Owzar K, Rankin C. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts). J Clin Oncol 2007; 25(18): 10004.
49. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41(12): 1751-1757.
50. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25(9): 1107-1113.
51. Eisenberg BL, I. Judson. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11: 465-475.
52. DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007; 25 (18S; June 20 Suppl): abstr. 10079.
53. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23(24): 5795-5804.
54. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol 2006; 18(4): 386-395.
55. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). J Clin Oncol (Meeting Abstracts) 2005; 23(16): 7.
56. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40(5): 689-695.
57. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21(23): 4342-4349.
58. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42(8): 1093-1103.
59. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16(4): 566-578.
60. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128(2): 270-279.
61. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24(29): 4764-4774.
62. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12(6):1743-1749.
63. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11(11): 4182-4190.
64. Utsunomiya T, Okamoto M, Yano S, et al. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case. Surg Today 2008; 38(1): 65-67.
65. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y,Hatakeyama K. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004; 90(11): 2059-2061.
66. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127(1): 294-299.
67. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64: 5913-5919.
68. Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004; 23: 139-152.
69. McLean SR, Gana-Weisz M, Hartzoulakis B, et al. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 2005; 4: 2008-2133.
70. Chen, L.L., Marshal, F.L.: US20067329495 (2006).
71. Roberts KG, Odell AF, Byrnes EM, et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007; 6(3): 1159-1166.
72. Wardelmann E, Biermann K, Merkelbach-Bruse B. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin Cancer Res 2006;12:6206
73. Wardelmann E, Thomas N, Merkelabch-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005; 6: 249-251.
74. Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 2007; 12(6): 719-726.
75. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55(4): 379-386.
76. Sleijfer S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Pract Oncol 2008; 5: 102-111.
77. Shankar S, van Sonnenberg E, Desai J, DiPiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235: 892-898.
78. Tang, P.C., Liang, C., Lipson, K.E., Miller, T.A., Li, X.: US20026573293 (2002).
79. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
80. Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol 2007. doi:10.1016/j/ejso.2007.10.011.
81. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
82. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Therap 2007; 7(29): 1338-53.
83. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46(7): 1116-1119.
84. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic(pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327-337.
85. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
86. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
87. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
88. Maki RG, Fletcher JA, Heinrich MC, et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (Meeting Abstracts)2005; 23(16 suppl): 9011.
89. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368(9544): 1329-1338.
90. George S, Blay JY, Casali PG, et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. J Clin Oncol (Meeting Abstracts) 2007; 25(18): 10015.
91. Morgan JA, Reichardt P, Kang YK, et al. Sunitinib (SU) in a worldwide treatment-use trial of patients with GIST: Safety and efficacy. In ASCO 2008 Gastrointestinal Cancers Symposium 2008. Orlando FA, USA.
92. Reichardt P, Kang YK, Ruka W, et al. Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy. J Clin Oncol 2007; 25(18S): Abs 10022.
93. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145(9): 660-664.
94. Heinrich M, Maki R,Corless C. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Proc Am Soc Clin Oncol 2006; 24 (520s): Abs. 9502.
95. Heinrich MC, Corless CL, Liegl B, et al. Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs). J Clin Oncol, ASCO Ann Meeting Proc 2007 Part I; 25 (18S): Abs. 10006.
96. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-2627.
97. Carter T, Wodicka L,Shah N. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011-11016.
98. Bornmann, W., Maxwell, D., Pa, A., Peng, Z., Estrov, Z.: WO08005877 ( 2008).
99. Manley, P.W.: WO07042465 (2007).
100. Le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834-1839. 101 Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
101. Dileo P, Bauer S, Van den Abbeele A, et al. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): Preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. in Gastrointestinal Cancers Symposium abstract 53, 2006.
102. Prenen H, Guetens G, de Boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006; 77(1): 11-16.
103. Weisberg E, Wright RD, Jiang J, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006; 131(6): 1734-1742.
104. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007; 13(16): 874-881.
105. Reichardt P, Casali PG, Blay J, et al. A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol (Meeting Abstracts) 2006; 24(18): 9545-.
106. Reichardt P, Casali PG, Blay J-Y, et al. A Phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update. Annals Oncol 2006; 17 (9): Abstr. 415P.
107. Von Mehren M, Reichardt P, Casali PG, et al. A Phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update. J Clin Oncol 2007; 25 (18S): Abstr. 10023.
108. Bui B, Blay J, Duffaud F, Hermine O, Le Cesne A. Preliminary efficacy and safety results of Masitinib administered, front line in patients with advanced GIST. A phase II study. J Clin Oncol 2007; 25(18S): 10025. 110 Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099-7109.
109. Strumberg D, Voliotis D, Moeller JG, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002; 40(12): 580-581.
110. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16(10): 1688-1694.
111. Wong KK, Eder JP, Clark J, et al. Final results of a phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and pharmacodynamics of BAY 43-9006 in repeated cycles of 1 week on/1 week off in patients with advanced, refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22: Abstr. 976.
112. Wilhelm, S.: WO07059154 (2007).
113. Nimeiri HS, Maki RG, Kasza K, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. In ASCO 2008 Gastrointestinal Cancers Symposium 2008; Orlando FL, USA.
114. Bold, G., Frei, J., Traxler, P., Altmann, K.-H., Mett, L.L., Stover, D.R., Wood, J.M.: US20016258812 (2001).
115. Thomas AL, Morgan B, Horsfield MA, et al. Steward. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23: 4162-4171.
116. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
117. Joensuu H, De Braud F, Coco P, et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008; 19(1): 173-177.
118. Das, J., Padmanabha, R., Chen, P., Norris, D.J., Doweyko, A.M.P., Barrish, J.C., Wityak, J., Lonbardo, L.J., Lee, F.Y.F.: US20036596746 (2003).
119. Lee, F.Y., Heinrich, M.C.: WO06135790 (2006).
120. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl -phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47(27): 6658-6661.
121. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66(1): 473-481.
122. Petti F, Thelemann A, Kahler J, et al. Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930. Mol Cancer Ther 2005; 4(8): 1186-1197.
123. Garton AJ, Crew AP, Franklin M, et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res2006; 66(2): 1015-1024.
124. Alva, G., Neervannan, S.: US20080039501 (2008).
125. Askew, B., Adams, J., Booker, S., Chen, G., Dipietro, L.V., Elbaum, D., Germain, J., Geuns-meyer, S.D., Handley, M., Habgood, G.J., Huang, Q., Kim, J.S., Li, A., Nishimura, N., Nomak, R., Patel, V.F., Riahi, B., Kim, J. L., Ning, X., Yang, K., Yuan, C.C.: US20056878714 (2005).
126. Polverino A, Coxon A, Starnes C, et al. AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts. Cancer Res 2006; 66(17): 8715-8721.
127. Rosen L, Kurzrock R, Jackson E, et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 2005; 23: 195.
128. Caravatti, G., Fredenhagen, A.: US19925093330 (1992).
129. Cools, J.: WO06024494 (2006).
130. Fabbro D, Parkinson D, Matter A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002; 2(4): 374-381.
131. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106(2): 721-724.
132. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int J Cancer 1989; 43: 851-856.
133. Reichardt P. A phase I/II trial of the oral PKC-inhibitor PKC412 in combination with imatinib mesylate (IM) in patients with gastrointestinal stromal tumors refractory to IM [abstract 3016]. Proc Am Soc Clin Oncol 2005; 23.
134. Dimitrijevic, S., Fletcher, J.A., Silberman, S.L.: WO05027971 (2005).
135. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10(2): 145-147.
136. Zhang L, Hannay JA, Liu J, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006; 66(17): 8770-8778. 139 Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003; 64(3): 266-274.
137. Alland, L., Manley, P.W., Mestan, J.: WO06132930 (2006).
138. Steinert DM, Oyarzo M, Wang X, et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006; 106(7): 1617-1623.
139. Van Oosterom A, Reichardt P, Blay J-Y, et al. A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update. J Clin Oncol (Meeting Abstracts) 2005; 23(16): 9033.
140. Wedge, S.R.: WO06035204 (2006).
141. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62(16): 4645-4655.
142. Drevs J, Muller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002; 62(14): 4015-4022.
143. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptorkinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005; 23:3002.
144. Hennequin, L, F., Ple, P., Stokes, E, S. E., McKerrecher, D.: WO0047212 (2000).
145. Wedge, S.R.: US2008015205 (2008).
146. Ikezoe T, Yang Y, Nishioka C, et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006; 97(9): 945-951.
147. Yang Y, Ikezoe T, Nishioka C, et al. ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci 2006; 97(12): 1404-1409.
148. Sambol EB, Ambrosini G, Geha RC, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006; 66(11): 5858-5866.
149. Nakatani H, Kobayashi M, Jin T, Taguchi T, Sugimoto T, Nakano T, Hamada S, Araki K. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci 2005; 96(2): 116-169.
150. Fumo, G., Neckers, L.: WO04037978 (2004).
151. Ying, W.: WO07139960 (2007).
152. Ying, W., Du, Z., Foley, K.: US20070087998 (2007).
153. Du, Z., Foley, K.: US20080004266 (2008).
154. Chimmanamada, D.U., Ying, W., Przewloka, T., Zhang, S., Foley, K., Du, Z., Zhou, D., Qin, S.: US20080004277 (2008).
155. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103(3): 1078-1084.
156. Bauer S, Yu LK, Demetri GD,Fletchcr JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66(18): 9153-9161.
157. Adams, J., Gao, Y., Evangelinos, A. T. G., Grenier, L., Pak, R.H., Porter, J.R., Wright, J.L: US20057282493 (2005).
158. Demetri GD, George S, Morgan JA, et al. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a Phase I trial. J Clin Oncol 2007; 25 (18S): Abstr. 10024.
159. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006; 103(46): 17408-17413.
160. Van den Abbeele AD, Yap JT, Grayzel DS, Walker J, Demetri GD. Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. J Clin Oncol 2007; 25 (18S): Abstr. 3530.